Role of YAP1 as a Marker of Sensitivity to Dual AKT and P70S6K Inhibition in Ovarian and Uterine Malignancies

YAP/TAZ at the Roots of Cancer

(2016) Francesca Zanconato et al.   CANCER CELL

Temsirolimus in women with platinum-refractory/resistant ovarian cancer or advanced/recurrent endometrial carcinoma. A phase II study of the AGO-study group (AGO-GYN8)

(2016) Günter Emons et al.   GYNECOLOGIC ONCOLOGY

YAP/TAZ for cancer therapy: Opportunities and challenges (Review)

(2015) LIWEN GUO et al.   INTERNATIONAL JOURNAL OF ONCOLOGY

Anastrozole and everolimus in advanced gynecologic and breast malignancies: activity and molecular alterations in the PI3K/AKT/mTOR pathway

(2015) Jennifer J. Wheler et al.   Oncotarget

PI3K and cancer: lessons, challenges and opportunities

(2014) David A. Fruman et al.   NATURE REVIEWS DRUG DISCOVERY

YAP Promotes Ovarian Cancer Cell Tumorigenesis and Is Indicative of a Poor Prognosis for Ovarian Cancer Patients

(2014) Yan Xia et al.   PLoS One

Yes-Associated Protein (YAP) Modulates Oncogenic Features and Radiation Sensitivity in Endometrial Cancer

(2014) Masahiro Tsujiura et al.   PLoS One

YAP/TEAD Co-Activator Regulated Pluripotency and Chemoresistance in Ovarian Cancer Initiated Cells

(2014) Yan Xia et al.   PLoS One

The role of LPA and YAP signaling in long-term migration of human ovarian cancer cells

(2013) Hui Cai et al.   Cell Communication and Signaling

Targeting Src and Tubulin in Mucinous Ovarian Carcinoma

(2013) T. Liu et al.   CLINICAL CANCER RESEARCH

New Strategies in Endometrial Cancer: Targeting the PI3K/mTOR Pathway--The Devil Is in the Details

(2013) A. P. Myers   CLINICAL CANCER RESEARCH

Role of Focal Adhesion Kinase in Regulating YB–1–Mediated Paclitaxel Resistance in Ovarian Cancer

(2013) Yu Kang et al.   JNCI-Journal of the National Cancer Institute

Integrated genomic characterization of endometrial carcinoma

(2013) Gad Getz et al.   NATURE

mTOR Signaling in Growth Control and Disease

(2012) Mathieu Laplante et al.   CELL

Molecular targets and targeted therapeutics in endometrial cancer

(2012) Britta Weigelt et al.   CURRENT OPINION IN ONCOLOGY

The functions and regulation of the PTEN tumour suppressor

(2012) Min Sup Song et al.   NATURE REVIEWS MOLECULAR CELL BIOLOGY

PIK3R1 (p85 ) Is Somatically Mutated at High Frequency in Primary Endometrial Cancer

(2011) M. E. Urick et al.   CANCER RESEARCH

Hallmarks of Cancer: The Next Generation

(2011) Douglas Hanahan et al.   CELL

A Unique Spectrum of Somatic PIK3CA (p110α) Mutations Within Primary Endometrial Carcinomas

(2011) Meghan L. Rudd et al.   CLINICAL CANCER RESEARCH

Molecular pathogenesis and extraovarian origin of epithelial ovarian cancer—Shifting the paradigm

(2011) Robert J. Kurman et al.   HUMAN PATHOLOGY

Integrated genomic analyses of ovarian carcinoma

(2011) D. Bell et al.   NATURE

Oncogenic YAP promotes radioresistance and genomic instability in medulloblastoma through IGF2-mediated Akt activation

(2011) A Fernandez-L et al.   ONCOGENE

The Hippo pathway transcriptional co-activator, YAP, is an ovarian cancer oncogene

(2011) X Zhang et al.   ONCOGENE

Drug Combination Studies and Their Synergy Quantification Using the Chou-Talalay Method

(2010) T.-C. Chou   CANCER RESEARCH

Akt inhibitors in clinical development for the treatment of cancer

(2010) Sumanta Kumar Pal et al.   EXPERT OPINION ON INVESTIGATIONAL DRUGS

Evidence that Inositol Polyphosphate 4-Phosphatase Type II Is a Tumor Suppressor that Inhibits PI3K Signaling

(2009) Christina Gewinner et al.   CANCER CELL